title: Hepatic glycogen synthesis is highly sensitive to phosphorylase activity: evidence from metabolic control analysis.
abstract: We used metabolic control analysis to determine the flux control coefficient of phosphorylase on glycogen synthesis in hepatocytes by titration with a specific phosphorylase inhibitor (CP-91149) or by expression of muscle phosphorylase using recombinant adenovirus. The muscle isoform was used because it is catalytically active in the b-state. CP-91149 inactivated phosphorylase with sequential activation of glycogen synthase. It increased glycogen synthesis by 7-fold at 5 mm glucose and by 2-fold at 20 mm glucose with a decrease in the concentration of glucose causing half-maximal rate (S(0.5)) from 26 to 19 mm. Muscle phosphorylase was expressed in hepatocytes mainly in the b-state. Low levels of phosphorylase expression inhibited glycogen synthesis by 50%, with little further inhibition at higher enzyme expression, and caused inactivation of glycogen synthase that was reversed by CP-91149. At endogenous activity, phosphorylase has a very high (greater than unity) negative control coefficient on glycogen synthesis, regardless of whether it is determined by enzyme inactivation or overexpression. This high control is attenuated by glucokinase overexpression, indicating dependence on other enzymes with high control. The high control coefficient of phosphorylase on glycogen synthesis affirms that phosphorylase is a strong candidate target for controlling hyperglycemia in type 2 diabetes in both the absorptive and postabsorptive states.
authors: Department of Diabetes, University of Newcastle upon Tyne, The Medical School, Newcastle upon Tyne NE2 4HH, United Kingdom.
authors: S
authors: S
authors: Aiston
authors: L
authors: L
authors: Hampson
authors: A M
authors: AM
authors: Gómez-Foix
authors: J J
authors: JJ
authors: Guinovart
authors: L
authors: L
authors: Agius
mesh_terms: D000249:Adenosine Monophosphate / Q000494:pharmacology; D000256:Adenoviridae / Q000235:genetics; D000577:Amides / Q000494:pharmacology; D000818:Animals; D002478:Cells, Cultured; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005934:Glucagon / Q000494:pharmacology; D005941:Glucokinase / Q000235:genetics / Q000378:metabolism; D005947:Glucose / Q000494:pharmacology; D006006:Glycogen Synthase / Q000235:genetics / Q000378:metabolism; D022781:Hepatocytes / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D007211:Indoles / Q000494:pharmacology; D008112:Liver Glycogen / Q000096:biosynthesis*; D008297:Male; D010763:Phosphorylase b / Q000037:antagonists & inhibitors / Q000378:metabolism; D006005:Phosphorylases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D014162:Transfection
chemical_list: D000577:Amides; C110844:CP 91149; D004791:Enzyme Inhibitors; D007211:Indoles; D008112:Liver Glycogen; D000249:Adenosine Monophosphate; D005934:Glucagon; D010763:Phosphorylase b; D006005:Phosphorylases; D006006:Glycogen Synthase; D005941:Glucokinase; D005947:Glucose